Výsledky vyhledávání - "Banerjee, Shreyan"

Akademický článek

No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Autor: Lowther, Daniel E. ^*, Houseman, E. Andres ^*, Han, Gang ^*, Kleanthous, Eleni ^*, Knoblock, Dawson ^*, Zhou, Xiangdong ^*, Banerjee, Shreyan ^*, Patel, Sagar ^*, Figueroa, David ^*

Publikováno v: In Blood 15 November 2022 140 Supplement 1:611-613

Zobrazit plný text záznamu